Generics Savings Once Again Could Help A Major Health Care Reform Bill
Executive Summary
A provision in the pending legislation on PBMs that would allow the US FDA to provide qualitative and quantitative information to ANDA sponsors about reference product's inactive ingredients could save hundreds of millions in spending.
You may also be interested in...
PBM Reforms: House Hearing Suggests Bipartisan Consensus On Legislative Policies Has Limits
There was lots of criticism of pharmacy benefit managers (and a fair amount of pharmaceutical manufacturers) at the oversight hearing. However, Democrats may be more cautious about preserving the benefits PBMs provide versus the downsides in developing reforms.
Are Fees The New Rebates? PhRMA Highlights Shifts In PBM Practices As House Tees Up Reform Vote
Pharmacy benefit managers are increasingly making money off new types of fees tied to list prices, drug industry lobby says, highlighting importance of delinking all PBM compensation from the cost of medicines. Most Congressional proposals in play do not include delinkage provision.
Biosimilars Could Give Brands the Boot Mid-Year Under Amendment Added to Senate PBM Reform Bill
However, the low CBO score attached to the measure may suggest PBMs might not be incentivized to follow through on the congressional permission.